OBJECTIVES: To determine the efficacy of subsequent disease modifying antirheumatic drug (DMARD) therapies after initial methotrexate (MTX) failure in patients with recent onset rheumatoid arthritis (RA), treated according to the DAS for 2 years. METHODS: In groups 1 and 2 of the BeSt study, 244 RA patients were initially treated with MTX 15-25 mg/week. Patients who discontinued MTX because of insufficient clinical response (disease activity score, DAS >2.4) or toxicity were classified as "MTX failures." In group 1, these patients switched to sulfasalazine (SSA), then leflunomide and finally to MTX + infliximab (IFX). In group 2, "MTX failures" added SSA to MTX, then hydroxychloroquine (HCQ), then prednisone, and eventually switched to MTX + IFX. "MTX successes" were patients who achieved a DAS </=2.4 after 2 years while still on MTX monotherapy. Total Sharp/van derHeijde score (TSS) progression from 0-2 years was assessed in "MTX failures" versus "MTX successes." RESULTS: After 2 years, 162/244 patients (66%) had discontinued MTX because of insufficient response or toxicity. Of these, 78% also failed on SSA (adding or switching), 87% subsequently failed on leflunomide (in group 1), and 64% on MTX + SSA + HCQ (in group 2). 34 of 48 patients (71%) in groups 1 and 2 were successfully treated with MTX + IFX. After 2 years, regardless of the "success" on subsequent DMARDs, " MTX failures" had a median TSS progression of 3 units (mean 9) versus 1 unit (mean 3) in "MTX successes" (p = 0.007). CONCLUSION: After failure on initial MTX, treatment with subsequent conventional DMARDs is unlikely to result in a DAS </=2.4 and allows progression of joint damage.
RCT Entities:
OBJECTIVES: To determine the efficacy of subsequent disease modifying antirheumatic drug (DMARD) therapies after initial methotrexate (MTX) failure in patients with recent onset rheumatoid arthritis (RA), treated according to the DAS for 2 years. METHODS: In groups 1 and 2 of the BeSt study, 244 RApatients were initially treated with MTX 15-25 mg/week. Patients who discontinued MTX because of insufficient clinical response (disease activity score, DAS >2.4) or toxicity were classified as "MTX failures." In group 1, these patients switched to sulfasalazine (SSA), then leflunomide and finally to MTX + infliximab (IFX). In group 2, "MTX failures" added SSA to MTX, then hydroxychloroquine (HCQ), then prednisone, and eventually switched to MTX + IFX. "MTX successes" were patients who achieved a DAS </=2.4 after 2 years while still on MTX monotherapy. Total Sharp/van der Heijde score (TSS) progression from 0-2 years was assessed in "MTX failures" versus "MTX successes." RESULTS: After 2 years, 162/244 patients (66%) had discontinued MTX because of insufficient response or toxicity. Of these, 78% also failed on SSA (adding or switching), 87% subsequently failed on leflunomide (in group 1), and 64% on MTX + SSA + HCQ (in group 2). 34 of 48 patients (71%) in groups 1 and 2 were successfully treated with MTX + IFX. After 2 years, regardless of the "success" on subsequent DMARDs, " MTX failures" had a median TSS progression of 3 units (mean 9) versus 1 unit (mean 3) in "MTX successes" (p = 0.007). CONCLUSION: After failure on initial MTX, treatment with subsequent conventional DMARDs is unlikely to result in a DAS </=2.4 and allows progression of joint damage.
Authors: Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans Journal: Arthritis Rheum Date: 2005-11
Authors: Judith A M Wessels; Jeska K de Vries-Bouwstra; Bas T Heijmans; P Eline Slagboom; Yvonne P M Goekoop-Ruiterman; Cornelia F Allaart; Pit J S M Kerstens; Derkjen van Zeben; Ferdinand C Breedveld; Ben A C Dijkmans; Tom W J Huizinga; Henk-Jan Guchelaar Journal: Arthritis Rheum Date: 2006-04
Authors: Hilary A Capell; Rajan Madhok; Duncan R Porter; Robin A L Munro; Iain B McInnes; John A Hunter; Malcolm Steven; Asad Zoma; Elaine Morrison; Martin Sambrook; Fat Wui Poon; Rosemary Hampson; Fiona McDonald; Ann Tierney; Neil Henderson; Ian Ford Journal: Ann Rheum Dis Date: 2006-08-22 Impact factor: 19.103
Authors: J S Smolen; J R Kalden; D L Scott; B Rozman; T K Kvien; A Larsen; I Loew-Friedrich; C Oed; R Rosenburg Journal: Lancet Date: 1999-01-23 Impact factor: 79.321
Authors: M E Weinblatt; J S Coblyn; D A Fox; P A Fraser; D E Holdsworth; D N Glass; D E Trentham Journal: N Engl J Med Date: 1985-03-28 Impact factor: 91.245
Authors: Vivian K Kawai; Carlos G Grijalva; Patrick G Arbogast; Jeffrey R Curtis; Daniel H Solomon; Elizabeth Delzell; Lang Chen; Rita Ouellet-Hellstrom; Lisa Herrinton; Liyan Liu; Edward F Mitchel; C Michael Stein; Marie R Griffin Journal: Arthritis Care Res (Hoboken) Date: 2011-10 Impact factor: 4.794
Authors: Bee Eng Tan; Ai Lee Lim; Sow Lai Kan; Chong Hong Lim; Esther Ee Ling Tsang; Shereen Suyin Ch'ng; Nadiah Mohd Noor; Nurulraziquin Mohd Jamid; Cheng Lay Teh; Rachel Joshua Thundyil; Yet Lin Loh; Hwee Cheng Chong; Swee Gaik Ong; Asmahan Mohamed Ismail; Yvonne Y L Lee; Suk Chyn Gun Journal: Rheumatol Int Date: 2017-07-10 Impact factor: 2.631
Authors: B Combe; C Codreanu; U Fiocco; M Gaubitz; P P Geusens; T K Kvien; K Pavelka; P N Sambrook; J S Smolen; R Khandker; A Singh; J Wajdula; S Fatenejad Journal: Ann Rheum Dis Date: 2008-09-15 Impact factor: 19.103
Authors: Kimme L Hyrich; Chris Deighton; Kath D Watson; Deborah P M Symmons; Mark Lunt Journal: Rheumatology (Oxford) Date: 2009-08-25 Impact factor: 7.580